News

ODU breaks ground on $184M biosciences building

Old Dominion University on Monday broke ground on the biggest capital project in the 95-year-old university’s history — a new biological sciences building.

The planned five-story, 162,586 square-foot building will be located on ‘s campus in , near the university’s Oceanography and Mills Godwin Life Sciences buildings.

ODU spokesperson Jonah Ross Grinkewitz said the $184 million project is funded by a state bond issue and will house classrooms, teaching laboratories, a 120-seat lecture hall and other student support spaces. State and campus leaders, and community members gathered Monday to commemorate the .

“Today would not be possible without significant support from the Commonwealth of Virginia,” said President Brian O. Hemphill in a Monday statement. “With the leadership and action of Gov. Youngkin and the General Assembly, a $184 million investment has been made in Old Dominion University, specifically our students, representing the largest in the history of our institution in terms of both scope and size.”

The building is meant to support faculty and student research in biomedical and ecological areas. As part of the project, the Arthur and Phyllis Kaplan Orchid Conservatory will be relocated within the biological sciences building with an added water feature and a two-story tropical display house. The exterior design incorporates an existing pond and features a terraced seating area.

A team that includes VMDO Architects, Ballinger and O’Shea Wilson Site Works designed the building. Newport News-based will serve as the project’s general contractor.

The building is expected to be ready for use in spring 2028.

Virginia Secretary of Education Aimee Guidera said the building embodies the ODU’s mission of being a “forward-focused, innovative and entrepreneurial research university.

“The pioneering biological research conducted at this state-of-the-art research and development hub will prepare students to succeed in their lives and careers beyond graduation,” Guidera added in a statement.

Read more here.

 

Recent News

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …

10/28/2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a biopharmaceutical company developing treatments for serious inflammatory diseases, today announced that it has changed its corporate name to Azora Therapeutics, Inc. The company’s common stock is expected to commence trading on The Nasdaq Capital Market under the new ticker symbol “AZR” on October 29, 2026. Azora has also launched …

10/28/2026

U.S. Bioscience Industry Powers Over $3 Trillion in Economic Output, New Report Finds

Today, the Biotechnology Innovation Organization (BIO) and the Council of State Bioscience Associations (CSBA) released new national and state-level data on the U.S. bioscience industry’s economic impact. The report, “The U.S. Bioscience Economy: Advancing Innovation and Strengthening States and Regions,” examines the industry’s economic footprint through employment, wages, business establishments, university research and development, access …